nodes	percent_of_prediction	percent_of_DWPC	metapath
Alendronate—PTPRE—portal vein—liver cancer	0.329	0.812	CbGeAlD
Alendronate—Osteonecrosis of jaw—Sorafenib—liver cancer	0.055	0.151	CcSEcCtD
Alendronate—ATP6V1A—embryo—liver cancer	0.0169	0.0415	CbGeAlD
Alendronate—PTPRE—liver—liver cancer	0.0166	0.0409	CbGeAlD
Alendronate—PTPN4—liver—liver cancer	0.0158	0.0389	CbGeAlD
Alendronate—ATP6V1A—Latent infection of Homo sapiens with Mycobacterium tuberculosis—LTF—liver cancer	0.015	0.0653	CbGpPWpGaD
Alendronate—PTPRE—IL6-mediated signaling events—BCL2L1—liver cancer	0.0139	0.0605	CbGpPWpGaD
Alendronate—ATP6V1A—Iron uptake and transport—SLC11A2—liver cancer	0.0139	0.0604	CbGpPWpGaD
Alendronate—PTPRS—liver—liver cancer	0.0135	0.0333	CbGeAlD
Alendronate—ATP6V1A—Iron uptake and transport—SLC40A1—liver cancer	0.0133	0.0576	CbGpPWpGaD
Alendronate—PTPRE—IL6-mediated signaling events—MAPK14—liver cancer	0.0132	0.0573	CbGpPWpGaD
Alendronate—Lymphopenia—Sorafenib—liver cancer	0.0124	0.0341	CcSEcCtD
Alendronate—Leukaemia—Epirubicin—liver cancer	0.00871	0.0239	CcSEcCtD
Alendronate—PTPRE—IL6-mediated signaling events—JUN—liver cancer	0.00838	0.0364	CbGpPWpGaD
Alendronate—Leukaemia—Doxorubicin—liver cancer	0.00805	0.0221	CcSEcCtD
Alendronate—FDPS—SREBP signalling—SCD—liver cancer	0.00781	0.0339	CbGpPWpGaD
Alendronate—ATP6V1A—liver—liver cancer	0.0078	0.0192	CbGeAlD
Alendronate—PTPRE—IL6-mediated signaling events—STAT3—liver cancer	0.00725	0.0315	CbGpPWpGaD
Alendronate—Gastrooesophageal reflux disease—Sorafenib—liver cancer	0.00702	0.0193	CcSEcCtD
Alendronate—Hypocalcaemia—Sorafenib—liver cancer	0.00693	0.019	CcSEcCtD
Alendronate—Drug interaction—Sorafenib—liver cancer	0.00684	0.0188	CcSEcCtD
Alendronate—PTPRE—IL6-mediated signaling events—MYC—liver cancer	0.00673	0.0292	CbGpPWpGaD
Alendronate—Oesophageal ulcer—Epirubicin—liver cancer	0.00643	0.0177	CcSEcCtD
Alendronate—Influenza like illness—Sorafenib—liver cancer	0.00616	0.0169	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—SHC3—liver cancer	0.00613	0.0266	CbGpPWpGaD
Alendronate—Oesophageal ulcer—Doxorubicin—liver cancer	0.00595	0.0163	CcSEcCtD
Alendronate—FDPS—liver—liver cancer	0.00588	0.0145	CbGeAlD
Alendronate—Retrosternal pain—Epirubicin—liver cancer	0.00582	0.016	CcSEcCtD
Alendronate—PTPRE—IL6-mediated signaling events—PIK3CA—liver cancer	0.00572	0.0248	CbGpPWpGaD
Alendronate—PTPRS—ECM proteoglycans—SERPINE1—liver cancer	0.00539	0.0234	CbGpPWpGaD
Alendronate—Retrosternal pain—Doxorubicin—liver cancer	0.00539	0.0148	CcSEcCtD
Alendronate—ATP6V1A—Iron uptake and transport—HMOX1—liver cancer	0.00533	0.0231	CbGpPWpGaD
Alendronate—PTPRE—IL6-mediated signaling events—IL6—liver cancer	0.00506	0.022	CbGpPWpGaD
Alendronate—PTPRE—IL6-mediated signaling events—AKT1—liver cancer	0.00467	0.0203	CbGpPWpGaD
Alendronate—Lymphopenia—Epirubicin—liver cancer	0.00458	0.0126	CcSEcCtD
Alendronate—Lymphopenia—Doxorubicin—liver cancer	0.00424	0.0117	CcSEcCtD
Alendronate—Dry skin—Sorafenib—liver cancer	0.00422	0.0116	CcSEcCtD
Alendronate—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.00415	0.0114	CcSEcCtD
Alendronate—Gastritis—Sorafenib—liver cancer	0.00408	0.0112	CcSEcCtD
Alendronate—Gastric ulcer—Epirubicin—liver cancer	0.00403	0.0111	CcSEcCtD
Alendronate—Dysphagia—Sorafenib—liver cancer	0.00398	0.0109	CcSEcCtD
Alendronate—Transaminases increased—Epirubicin—liver cancer	0.00385	0.0106	CcSEcCtD
Alendronate—Abdominal discomfort—Sorafenib—liver cancer	0.00382	0.0105	CcSEcCtD
Alendronate—Gastric ulcer—Doxorubicin—liver cancer	0.00373	0.0103	CcSEcCtD
Alendronate—PTPRS—Extracellular matrix organization—ADAM17—liver cancer	0.00365	0.0159	CbGpPWpGaD
Alendronate—FDPS—Activation of gene expression by SREBF (SREBP)—PPARA—liver cancer	0.00365	0.0158	CbGpPWpGaD
Alendronate—Transaminases increased—Doxorubicin—liver cancer	0.00357	0.0098	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.00352	0.00967	CcSEcCtD
Alendronate—Stomatitis—Sorafenib—liver cancer	0.00346	0.00951	CcSEcCtD
Alendronate—PTPRS—Extracellular matrix organization—COL1A1—liver cancer	0.00342	0.0148	CbGpPWpGaD
Alendronate—PTPRS—ECM proteoglycans—TGFB1—liver cancer	0.0034	0.0148	CbGpPWpGaD
Alendronate—Hypercalcaemia—Epirubicin—liver cancer	0.00337	0.00928	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—MYO5B—liver cancer	0.00327	0.0142	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.00327	0.0142	CbGpPWpGaD
Alendronate—Haemoglobin—Sorafenib—liver cancer	0.0032	0.0088	CcSEcCtD
Alendronate—Haemorrhage—Sorafenib—liver cancer	0.00319	0.00876	CcSEcCtD
Alendronate—Hypercalcaemia—Doxorubicin—liver cancer	0.00312	0.00858	CcSEcCtD
Alendronate—Erythema multiforme—Sorafenib—liver cancer	0.00301	0.00828	CcSEcCtD
Alendronate—FDPS—Regulation of cholesterol biosynthesis by SREBP (SREBF)—PPARA—liver cancer	0.00291	0.0126	CbGpPWpGaD
Alendronate—Alopecia—Sorafenib—liver cancer	0.00282	0.00774	CcSEcCtD
Alendronate—Erythema—Sorafenib—liver cancer	0.00277	0.00762	CcSEcCtD
Alendronate—Dysgeusia—Sorafenib—liver cancer	0.00272	0.00747	CcSEcCtD
Alendronate—Muscle spasms—Sorafenib—liver cancer	0.00267	0.00733	CcSEcCtD
Alendronate—Anaemia—Sorafenib—liver cancer	0.00256	0.00705	CcSEcCtD
Alendronate—Hypocalcaemia—Epirubicin—liver cancer	0.00256	0.00704	CcSEcCtD
Alendronate—Angioedema—Sorafenib—liver cancer	0.00253	0.00697	CcSEcCtD
Alendronate—Ulcer—Epirubicin—liver cancer	0.00248	0.00681	CcSEcCtD
Alendronate—Musculoskeletal pain—Epirubicin—liver cancer	0.00237	0.00652	CcSEcCtD
Alendronate—Hypocalcaemia—Doxorubicin—liver cancer	0.00237	0.00651	CcSEcCtD
Alendronate—Myalgia—Sorafenib—liver cancer	0.00236	0.00649	CcSEcCtD
Alendronate—Ulcer—Doxorubicin—liver cancer	0.00229	0.0063	CcSEcCtD
Alendronate—Melaena—Epirubicin—liver cancer	0.00229	0.0063	CcSEcCtD
Alendronate—Influenza like illness—Epirubicin—liver cancer	0.00228	0.00626	CcSEcCtD
Alendronate—Infection—Sorafenib—liver cancer	0.00225	0.00618	CcSEcCtD
Alendronate—Musculoskeletal pain—Doxorubicin—liver cancer	0.0022	0.00604	CcSEcCtD
Alendronate—ATP6V1A—Disease—APCS—liver cancer	0.00215	0.00934	CbGpPWpGaD
Alendronate—Oesophagitis—Epirubicin—liver cancer	0.00214	0.00589	CcSEcCtD
Alendronate—Melaena—Doxorubicin—liver cancer	0.00212	0.00582	CcSEcCtD
Alendronate—Influenza like illness—Doxorubicin—liver cancer	0.00211	0.00579	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00206	0.00567	CcSEcCtD
Alendronate—Dyspepsia—Sorafenib—liver cancer	0.00199	0.00548	CcSEcCtD
Alendronate—Oesophagitis—Doxorubicin—liver cancer	0.00198	0.00545	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.00196	0.00851	CbGpPWpGaD
Alendronate—FDPS—SREBP signalling—PPARG—liver cancer	0.00195	0.00846	CbGpPWpGaD
Alendronate—Photosensitivity—Epirubicin—liver cancer	0.00194	0.00533	CcSEcCtD
Alendronate—Constipation—Sorafenib—liver cancer	0.00194	0.00532	CcSEcCtD
Alendronate—Pain—Sorafenib—liver cancer	0.00194	0.00532	CcSEcCtD
Alendronate—PTPRS—Extracellular matrix organization—KDR—liver cancer	0.00192	0.00833	CbGpPWpGaD
Alendronate—Gastrointestinal pain—Sorafenib—liver cancer	0.00185	0.00509	CcSEcCtD
Alendronate—Urticaria—Sorafenib—liver cancer	0.0018	0.00494	CcSEcCtD
Alendronate—Photosensitivity—Doxorubicin—liver cancer	0.00179	0.00493	CcSEcCtD
Alendronate—Abdominal pain—Sorafenib—liver cancer	0.00179	0.00492	CcSEcCtD
Alendronate—Body temperature increased—Sorafenib—liver cancer	0.00179	0.00492	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00167	0.00727	CbGpPWpGaD
Alendronate—Hypersensitivity—Sorafenib—liver cancer	0.00167	0.00458	CcSEcCtD
Alendronate—PTPRS—Extracellular matrix organization—CDH1—liver cancer	0.00163	0.00706	CbGpPWpGaD
Alendronate—Asthenia—Sorafenib—liver cancer	0.00162	0.00446	CcSEcCtD
Alendronate—Pruritus—Sorafenib—liver cancer	0.0016	0.0044	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.0016	0.00694	CbGpPWpGaD
Alendronate—PTPRS—Extracellular matrix organization—MMP2—liver cancer	0.00157	0.0068	CbGpPWpGaD
Alendronate—Dry skin—Epirubicin—liver cancer	0.00156	0.00429	CcSEcCtD
Alendronate—Diarrhoea—Sorafenib—liver cancer	0.00155	0.00426	CcSEcCtD
Alendronate—FDPS—SREBP signalling—MTOR—liver cancer	0.00155	0.00672	CbGpPWpGaD
Alendronate—PTPRS—Extracellular matrix organization—SERPINE1—liver cancer	0.00154	0.00667	CbGpPWpGaD
Alendronate—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00153	0.00421	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—ANXA2—liver cancer	0.00153	0.00665	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—ATP7B—liver cancer	0.00153	0.00665	CbGpPWpGaD
Alendronate—Gastritis—Epirubicin—liver cancer	0.00151	0.00414	CcSEcCtD
Alendronate—Dizziness—Sorafenib—liver cancer	0.0015	0.00411	CcSEcCtD
Alendronate—Abdominal distension—Epirubicin—liver cancer	0.00148	0.00407	CcSEcCtD
Alendronate—Dysphagia—Epirubicin—liver cancer	0.00147	0.00404	CcSEcCtD
Alendronate—Asthma—Epirubicin—liver cancer	0.00147	0.00404	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00145	0.00629	CbGpPWpGaD
Alendronate—Dry skin—Doxorubicin—liver cancer	0.00144	0.00397	CcSEcCtD
Alendronate—Vomiting—Sorafenib—liver cancer	0.00144	0.00396	CcSEcCtD
Alendronate—Rash—Sorafenib—liver cancer	0.00143	0.00392	CcSEcCtD
Alendronate—Dermatitis—Sorafenib—liver cancer	0.00143	0.00392	CcSEcCtD
Alendronate—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00142	0.0039	CcSEcCtD
Alendronate—Headache—Sorafenib—liver cancer	0.00142	0.0039	CcSEcCtD
Alendronate—Gastritis—Doxorubicin—liver cancer	0.00139	0.00383	CcSEcCtD
Alendronate—Abdominal distension—Doxorubicin—liver cancer	0.00137	0.00377	CcSEcCtD
Alendronate—Asthma—Doxorubicin—liver cancer	0.00136	0.00374	CcSEcCtD
Alendronate—Dysphagia—Doxorubicin—liver cancer	0.00136	0.00374	CcSEcCtD
Alendronate—Nausea—Sorafenib—liver cancer	0.00134	0.0037	CcSEcCtD
Alendronate—Photosensitivity reaction—Epirubicin—liver cancer	0.00134	0.00369	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—RAF1—liver cancer	0.00131	0.00568	CbGpPWpGaD
Alendronate—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.0013	0.00357	CcSEcCtD
Alendronate—Stomatitis—Epirubicin—liver cancer	0.00128	0.00351	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—PIK3CB—liver cancer	0.00128	0.00554	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling by Insulin receptor—MTOR—liver cancer	0.00128	0.00554	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.00126	0.00548	CbGpPWpGaD
Alendronate—PTPRS—Extracellular matrix organization—CASP3—liver cancer	0.00125	0.00541	CbGpPWpGaD
Alendronate—Photosensitivity reaction—Doxorubicin—liver cancer	0.00124	0.00341	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.00122	0.00529	CbGpPWpGaD
Alendronate—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.0012	0.00331	CcSEcCtD
Alendronate—Haemoglobin—Epirubicin—liver cancer	0.00118	0.00325	CcSEcCtD
Alendronate—Stomatitis—Doxorubicin—liver cancer	0.00118	0.00325	CcSEcCtD
Alendronate—Haemorrhage—Epirubicin—liver cancer	0.00118	0.00324	CcSEcCtD
Alendronate—PTPRS—Extracellular matrix organization—MMP9—liver cancer	0.00118	0.00511	CbGpPWpGaD
Alendronate—Oedema peripheral—Epirubicin—liver cancer	0.00116	0.00319	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—CHN2—liver cancer	0.00114	0.00496	CbGpPWpGaD
Alendronate—Erythema multiforme—Epirubicin—liver cancer	0.00111	0.00306	CcSEcCtD
Alendronate—Haemoglobin—Doxorubicin—liver cancer	0.00109	0.00301	CcSEcCtD
Alendronate—Haemorrhage—Doxorubicin—liver cancer	0.00109	0.00299	CcSEcCtD
Alendronate—Oedema peripheral—Doxorubicin—liver cancer	0.00107	0.00295	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—IFT88—liver cancer	0.00104	0.00453	CbGpPWpGaD
Alendronate—Alopecia—Epirubicin—liver cancer	0.00104	0.00286	CcSEcCtD
Alendronate—Erythema multiforme—Doxorubicin—liver cancer	0.00103	0.00283	CcSEcCtD
Alendronate—Erythema—Epirubicin—liver cancer	0.00102	0.00282	CcSEcCtD
Alendronate—Flatulence—Epirubicin—liver cancer	0.00101	0.00278	CcSEcCtD
Alendronate—Dysgeusia—Epirubicin—liver cancer	0.001	0.00276	CcSEcCtD
Alendronate—Muscle spasms—Epirubicin—liver cancer	0.000985	0.00271	CcSEcCtD
Alendronate—PTPRS—Extracellular matrix organization—TGFB1—liver cancer	0.00097	0.00421	CbGpPWpGaD
Alendronate—Alopecia—Doxorubicin—liver cancer	0.000963	0.00265	CcSEcCtD
Alendronate—Ill-defined disorder—Epirubicin—liver cancer	0.000951	0.00261	CcSEcCtD
Alendronate—Erythema—Doxorubicin—liver cancer	0.000948	0.00261	CcSEcCtD
Alendronate—Anaemia—Epirubicin—liver cancer	0.000947	0.0026	CcSEcCtD
Alendronate—FDPS—SREBP signalling—PIK3CA—liver cancer	0.000943	0.00409	CbGpPWpGaD
Alendronate—Flatulence—Doxorubicin—liver cancer	0.000934	0.00257	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000931	0.00404	CbGpPWpGaD
Alendronate—Dysgeusia—Doxorubicin—liver cancer	0.000929	0.00255	CcSEcCtD
Alendronate—FDPS—Metabolism—UGDH—liver cancer	0.000928	0.00403	CbGpPWpGaD
Alendronate—Malaise—Epirubicin—liver cancer	0.000924	0.00254	CcSEcCtD
Alendronate—Vertigo—Epirubicin—liver cancer	0.000921	0.00253	CcSEcCtD
Alendronate—Muscle spasms—Doxorubicin—liver cancer	0.000912	0.00251	CcSEcCtD
Alendronate—Ill-defined disorder—Doxorubicin—liver cancer	0.00088	0.00242	CcSEcCtD
Alendronate—Anaemia—Doxorubicin—liver cancer	0.000877	0.00241	CcSEcCtD
Alendronate—Chest pain—Epirubicin—liver cancer	0.000873	0.0024	CcSEcCtD
Alendronate—Myalgia—Epirubicin—liver cancer	0.000873	0.0024	CcSEcCtD
Alendronate—FDPS—Metabolism—EPT1—liver cancer	0.000873	0.00379	CbGpPWpGaD
Alendronate—Discomfort—Epirubicin—liver cancer	0.000862	0.00237	CcSEcCtD
Alendronate—Malaise—Doxorubicin—liver cancer	0.000855	0.00235	CcSEcCtD
Alendronate—Vertigo—Doxorubicin—liver cancer	0.000852	0.00234	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—KRAS—liver cancer	0.000847	0.00368	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—LTF—liver cancer	0.00084	0.00365	CbGpPWpGaD
Alendronate—Infection—Epirubicin—liver cancer	0.000831	0.00228	CcSEcCtD
Alendronate—FDPS—Metabolism—TAT—liver cancer	0.000827	0.00359	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000814	0.00353	CbGpPWpGaD
Alendronate—Chest pain—Doxorubicin—liver cancer	0.000807	0.00222	CcSEcCtD
Alendronate—Myalgia—Doxorubicin—liver cancer	0.000807	0.00222	CcSEcCtD
Alendronate—Discomfort—Doxorubicin—liver cancer	0.000798	0.00219	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—PIK3CA—liver cancer	0.000778	0.00338	CbGpPWpGaD
Alendronate—FDPS—SREBP signalling—AKT1—liver cancer	0.00077	0.00334	CbGpPWpGaD
Alendronate—Infection—Doxorubicin—liver cancer	0.000769	0.00211	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000762	0.00209	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—CYCS—liver cancer	0.000738	0.0032	CbGpPWpGaD
Alendronate—Dyspepsia—Epirubicin—liver cancer	0.000736	0.00202	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—HRAS—liver cancer	0.00072	0.00313	CbGpPWpGaD
Alendronate—Constipation—Epirubicin—liver cancer	0.000715	0.00197	CcSEcCtD
Alendronate—Pain—Epirubicin—liver cancer	0.000715	0.00197	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000705	0.00194	CcSEcCtD
Alendronate—Feeling abnormal—Epirubicin—liver cancer	0.000689	0.00189	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—IL6—liver cancer	0.000689	0.00299	CbGpPWpGaD
Alendronate—Gastrointestinal pain—Epirubicin—liver cancer	0.000684	0.00188	CcSEcCtD
Alendronate—Dyspepsia—Doxorubicin—liver cancer	0.000681	0.00187	CcSEcCtD
Alendronate—Urticaria—Epirubicin—liver cancer	0.000665	0.00183	CcSEcCtD
Alendronate—Constipation—Doxorubicin—liver cancer	0.000662	0.00182	CcSEcCtD
Alendronate—Pain—Doxorubicin—liver cancer	0.000662	0.00182	CcSEcCtD
Alendronate—Body temperature increased—Epirubicin—liver cancer	0.000661	0.00182	CcSEcCtD
Alendronate—Abdominal pain—Epirubicin—liver cancer	0.000661	0.00182	CcSEcCtD
Alendronate—ATP6V1A—Disease—ALDOB—liver cancer	0.000649	0.00282	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000642	0.00279	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—SHC3—liver cancer	0.00064	0.00278	CbGpPWpGaD
Alendronate—Feeling abnormal—Doxorubicin—liver cancer	0.000638	0.00175	CcSEcCtD
Alendronate—Gastrointestinal pain—Doxorubicin—liver cancer	0.000633	0.00174	CcSEcCtD
Alendronate—Hypersensitivity—Epirubicin—liver cancer	0.000616	0.00169	CcSEcCtD
Alendronate—Urticaria—Doxorubicin—liver cancer	0.000615	0.00169	CcSEcCtD
Alendronate—Body temperature increased—Doxorubicin—liver cancer	0.000612	0.00168	CcSEcCtD
Alendronate—Abdominal pain—Doxorubicin—liver cancer	0.000612	0.00168	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.000609	0.00264	CbGpPWpGaD
Alendronate—Asthenia—Epirubicin—liver cancer	0.0006	0.00165	CcSEcCtD
Alendronate—Pruritus—Epirubicin—liver cancer	0.000592	0.00163	CcSEcCtD
Alendronate—Diarrhoea—Epirubicin—liver cancer	0.000572	0.00157	CcSEcCtD
Alendronate—Hypersensitivity—Doxorubicin—liver cancer	0.00057	0.00157	CcSEcCtD
Alendronate—FDPS—Metabolism—GLUL—liver cancer	0.000562	0.00244	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CPT1B—liver cancer	0.000562	0.00244	CbGpPWpGaD
Alendronate—Asthenia—Doxorubicin—liver cancer	0.000555	0.00153	CcSEcCtD
Alendronate—Dizziness—Epirubicin—liver cancer	0.000553	0.00152	CcSEcCtD
Alendronate—Pruritus—Doxorubicin—liver cancer	0.000548	0.00151	CcSEcCtD
Alendronate—FDPS—Metabolism—NR1H4—liver cancer	0.000542	0.00235	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GSTA3—liver cancer	0.000533	0.00231	CbGpPWpGaD
Alendronate—Vomiting—Epirubicin—liver cancer	0.000532	0.00146	CcSEcCtD
Alendronate—Diarrhoea—Doxorubicin—liver cancer	0.00053	0.00146	CcSEcCtD
Alendronate—Rash—Epirubicin—liver cancer	0.000527	0.00145	CcSEcCtD
Alendronate—Dermatitis—Epirubicin—liver cancer	0.000527	0.00145	CcSEcCtD
Alendronate—Headache—Epirubicin—liver cancer	0.000524	0.00144	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—PPARA—liver cancer	0.000518	0.00225	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—ADAM17—liver cancer	0.000513	0.00223	CbGpPWpGaD
Alendronate—Dizziness—Doxorubicin—liver cancer	0.000512	0.00141	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—FST—liver cancer	0.000497	0.00216	CbGpPWpGaD
Alendronate—Nausea—Epirubicin—liver cancer	0.000497	0.00137	CcSEcCtD
Alendronate—Vomiting—Doxorubicin—liver cancer	0.000492	0.00135	CcSEcCtD
Alendronate—Rash—Doxorubicin—liver cancer	0.000488	0.00134	CcSEcCtD
Alendronate—Dermatitis—Doxorubicin—liver cancer	0.000488	0.00134	CcSEcCtD
Alendronate—FDPS—Metabolism—GSTA4—liver cancer	0.000487	0.00212	CbGpPWpGaD
Alendronate—Headache—Doxorubicin—liver cancer	0.000485	0.00133	CcSEcCtD
Alendronate—ATP6V1A—Disease—PSMD10—liver cancer	0.000482	0.00209	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PSMA4—liver cancer	0.000482	0.00209	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	0.000476	0.00207	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GSTA2—liver cancer	0.000475	0.00206	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TRIO—liver cancer	0.000474	0.00206	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—GOT2—liver cancer	0.000469	0.00204	CbGpPWpGaD
Alendronate—Nausea—Doxorubicin—liver cancer	0.00046	0.00126	CcSEcCtD
Alendronate—FDPS—Metabolism—GSTA1—liver cancer	0.000458	0.00199	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CCR4—liver cancer	0.000454	0.00197	CbGpPWpGaD
Alendronate—FDPS—Metabolism—NAT2—liver cancer	0.000453	0.00197	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PPARA—liver cancer	0.000436	0.00189	CbGpPWpGaD
Alendronate—FDPS—Metabolism—ALDOB—liver cancer	0.000434	0.00189	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CRABP1—liver cancer	0.000415	0.0018	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—GOT1—liver cancer	0.000405	0.00176	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—ALB—liver cancer	0.000385	0.00167	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PRKCE—liver cancer	0.000374	0.00162	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	0.000373	0.00162	CbGpPWpGaD
Alendronate—FDPS—Metabolism—HPGDS—liver cancer	0.000362	0.00157	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PPARG—liver cancer	0.00036	0.00156	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—ADAM17—liver cancer	0.000359	0.00156	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—RAF1—liver cancer	0.000348	0.00151	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PSMD10—liver cancer	0.000338	0.00147	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PSMA4—liver cancer	0.000338	0.00147	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	0.000328	0.00142	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—H2AFX—liver cancer	0.000326	0.00141	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—ALB—liver cancer	0.000324	0.00141	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PSMA4—liver cancer	0.000323	0.0014	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PSMD10—liver cancer	0.000323	0.0014	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GOT2—liver cancer	0.000314	0.00136	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MTHFR—liver cancer	0.000295	0.00128	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CYP2E1—liver cancer	0.000295	0.00128	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—TERT—liver cancer	0.000295	0.00128	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	0.000286	0.00124	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CYCS—liver cancer	0.000276	0.0012	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GGT1—liver cancer	0.000271	0.00118	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GOT1—liver cancer	0.000271	0.00118	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PRKCE—liver cancer	0.000262	0.00114	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—APC—liver cancer	0.000248	0.00108	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—IGF2—liver cancer	0.000248	0.00108	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GSTP1—liver cancer	0.000244	0.00106	CbGpPWpGaD
Alendronate—FDPS—Metabolism—HMOX1—liver cancer	0.00024	0.00104	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—BRAF—liver cancer	0.000233	0.00101	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CSF2—liver cancer	0.000231	0.00101	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—H2AFX—liver cancer	0.000228	0.000991	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GSTM1—liver cancer	0.000224	0.000972	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PIK3CD—liver cancer	0.000218	0.000948	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—SERPINE1—liver cancer	0.000216	0.000937	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CYP1A1—liver cancer	0.000212	0.000921	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TERT—liver cancer	0.000206	0.000896	CbGpPWpGaD
Alendronate—FDPS—Metabolism—MTHFR—liver cancer	0.000198	0.000859	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—RAF1—liver cancer	0.000195	0.000846	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PPARA—liver cancer	0.000194	0.000843	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MTOR—liver cancer	0.00019	0.000826	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PIK3CB—liver cancer	0.00019	0.000826	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—KDR—liver cancer	0.000189	0.00082	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MAPK14—liver cancer	0.000187	0.000814	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—ESR1—liver cancer	0.000184	0.000799	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—F2—liver cancer	0.000182	0.000789	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CDKN1B—liver cancer	0.000179	0.000775	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	0.000174	0.000757	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—APC—liver cancer	0.000174	0.000755	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PIK3CG—liver cancer	0.000174	0.000755	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CTNNB1—liver cancer	0.000169	0.000732	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PIK3CG—liver cancer	0.000166	0.000722	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CDKN1A—liver cancer	0.000165	0.000715	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—BRAF—liver cancer	0.000163	0.00071	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PPARG—liver cancer	0.00016	0.000697	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PIK3CD—liver cancer	0.000153	0.000664	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—SERPINE1—liver cancer	0.000151	0.000656	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—STAT3—liver cancer	0.000147	0.000638	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PIK3CD—liver cancer	0.000146	0.000635	CbGpPWpGaD
Alendronate—FDPS—Metabolism—ALB—liver cancer	0.000144	0.000626	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MYC—liver cancer	0.000137	0.000593	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—RAF1—liver cancer	0.000136	0.000592	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—TGFB1—liver cancer	0.000136	0.000592	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PIK3CB—liver cancer	0.000133	0.000578	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MTOR—liver cancer	0.000133	0.000578	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PIK3CB—liver cancer	0.000127	0.000553	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—KRAS—liver cancer	0.000126	0.000548	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CDKN1B—liver cancer	0.000125	0.000543	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CASP3—liver cancer	0.000123	0.000532	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—IL2—liver cancer	0.000122	0.000531	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CCND1—liver cancer	0.000119	0.000518	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—JUN—liver cancer	0.000119	0.000517	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CTNNB1—liver cancer	0.000118	0.000513	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PIK3CA—liver cancer	0.000116	0.000504	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MMP9—liver cancer	0.000116	0.000503	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CDKN1A—liver cancer	0.000115	0.000501	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MAPK8—liver cancer	0.000113	0.000489	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—HRAS—liver cancer	0.000107	0.000466	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—VEGFA—liver cancer	0.000104	0.000451	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—STAT3—liver cancer	0.000103	0.000447	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—IL6—liver cancer	0.000103	0.000446	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MYC—liver cancer	9.57e-05	0.000415	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TGFB1—liver cancer	9.54e-05	0.000414	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—AKT1—liver cancer	9.47e-05	0.000411	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—KRAS—liver cancer	8.84e-05	0.000384	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PIK3CA—liver cancer	8.12e-05	0.000353	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TP53—liver cancer	7.86e-05	0.000341	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PIK3CA—liver cancer	7.76e-05	0.000337	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—HRAS—liver cancer	7.51e-05	0.000326	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—IL6—liver cancer	7.19e-05	0.000312	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—AKT1—liver cancer	6.63e-05	0.000288	CbGpPWpGaD
Alendronate—FDPS—Metabolism—AKT1—liver cancer	6.34e-05	0.000275	CbGpPWpGaD
